Frovatriptan inhalation aerosol powder, preparation method thereof and application of powder

Abstract

The invention discloses frovatriptan inhalation aerosol powder which comprises frovatriptan micro-powder and carrier micro-powder. The particle sizes of the frovatriptan micro-powder are d10=0.8-1.8 micrometers, d50=1.5-4.5 micrometers and d90=3.0-9.0 micrometers, the particle sizes of more than 95% of the frovatriptan micro-powder are smaller than 10 micrometers, the particle sizes of the carrier micro-powder are d10=20-45 micrometers, d50=80-110 micrometers and d90=120-180 micrometers, and the weight ratio of the frovatriptan micro-powder to the carrier micro-powder is 1:(1-1000). A preparation method of the frovatriptan inhalation aerosol powder includes the steps of frovatriptan micronizing, carrier micronizing, carrier granulation, mixing and sub-packaging. Capsules are filled with the blended powder by a micro-capsule filling machine, and the powder is sub-packaged to prepare the capsules containing the frovatriptan inhalation aerosol powder, and the filling amount of each capsule is 1-200mg. The frovatriptan inhalation aerosol powder includes a nasal inhalation mode and an oral inhalation mode, and frovatriptan can exist in a physiological salt form. The frovatriptan inhalation aerosol powder is high in bioavailability and rapid in effect.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, and relates to an inhalation powder, especially a frovatriptan inhalation powder and its preparation method and application. Background technique [0002] Migraine is a common clinical chronic neurovascular disease characterized by recurrent, pulsating severe headache on one or both sides. It lasts for 4 to 72 hours. Before the attack, there are often auras such as blurred vision, flashes of light, hemianopia, hemifacial and limb numbness. During the attack, it is often accompanied by symptoms such as rapid heart rate, pale complexion, nausea, vomiting, photophobia, phonophobia, etc., according to the World Health Organization According to the 2013 Global Burden of Disease Survey, migraine is the third most common disease in humans and the sixth most disabling disease in the world, affecting up to 15% of the global population. About 1 / 3 of migraine patients may have nervous s...

AI Technical Summary

Problems solved by technology

[0006] Since tablets, granules, capsules, injections, etc. are all drugs that are metabolized by the whole body, the dosage of their efficacy will be affected by problems such as absorption. At the same time, because they are drugs that are metabolized by the whole body, they are likely to cause cardiovascular, allergies, etc. Side effects, and cause problems such as low bioavailability and slow onset of action

[0007] Therefore, need to provide a kind of new drug that effectively solves the problem of low bioavailability and slow onset of action

Images